CompletedPhase 1DMT

Clinical Study of DMT in Healthy Adults

Sponsored by Biomind Labs Inc.

NCT ID
NCT05573568
Target Enrollment
27 participants
Start Date
2022-06-01
Est. Completion
2022-11-14

About This Study

This study aims to evaluate the acute and subacute effects of an inhaled N, N-Dimethyltryptamine in healthy individuals.

Conditions Studied

Healthy Volunteers

Interventions

  • •N,N-Dimethyltryptamine

Eligibility

Age:18 Years - 65 Years
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria:

* prior experience with N,N-Dimethyltryptamine (DMT)
* present proof of vaccination against COVID-19 (Coronavírus)

Exclusion Criteria:

* heart failure
* liver failure
* kidney failure
* resistant hypertension
* arrhythmia
* valvular heart disease
* chronic obstructive pulmonary disease
* asthma
* severe obesity
* epilepsy
* pregnancy
* thyroid disorders
* family diagnosis or suspicion of genetic monoamine oxidase deficiency
* previous adverse response to psychedelic substances
* present or past symptoms or family members with a psychotic disorder
* dissociative identity disorder
* bipolar disorder
* prodromal symptoms of schizophrenia
* abuse of alcohol or other psychoactive substances, except tobacco
* acute or sub-acute risk of suicide
* flu-like symptoms

Study Locations (1)

Hospital Universitário Onofre Lopes
Natal, Rio Grande do Norte, Brazil

This trial is not recruiting

This study has completed enrollment. Check back for results or find similar trials.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source

Clinical Study of DMT in Healthy Adults | Huxley